Spire Health Appoints Dana Cambra as New Senior Vice President of Research and Development to Drive Rapid Growth and Innovation
Spire Health, the leading digital healthcare company for continuous respiratory remote patient monitoring, today announced that Dana Cambra has been appointed as Senior Vice President of Research and Development. Mr. Cambra will lead the development of Spire Health’s remote patient monitoring platform, adding key capabilities such as the upcoming launch of revolutionary new algorithms, all in support of the rapid adoption of the Spire Health platform by pulmonologists and their patients.
“Dana Cambra has vast R&D expertise in rapid growth companies and deep knowledge of healthcare,” said Chris Raanes, Chief Executive Officer, Spire Health. “He is an ideal addition to our team as we partner with pulmonologists, aiming to improve the lives of patients through earlier intervention. We are delighted to welcome Dana as we usher in the next wave of Spire Health innovation.”
Dana Cambra has more than 30 years of research and development experience with leading healthcare companies. As Vice President of Research and Development at Dexcom, where he managed a team of 300 engineers in 4 locations, Mr. Cambra revolutionized diabetes management, leading the development of the innovative Dexcom G6 Continuous Glucose Monitor (CGM). Prior to his tenure at Dexcom, Mr. Cambra held leadership positions at Align Technology, Pharsight, and Stentor (purchased by Philips). Mr. Cambra received his Master of Engineering degree from University of California, Berkley and his Bachelor of Engineering and Bachelor of Applied Mathematics degrees from Massachusetts Institute of Technology.
“I am excited to join Spire Health in our mission to improve the lives of patient’s living with chronic respiratory diseases,” said Dana Cambra. “The Spire Health remote patient monitoring platform pairs innovative 100% passive sensing with revolutionary respiratory algorithms to achieve unparalleled monitoring. Spire Health is quickly becoming a standard of care for patients living with COPD and chronic respiratory conditions, and I look forward to helping our team make this a reality for all those in need.”